Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17861182 | 0.98 | — | — | |
| SCHEMBL17447 | 0.87 | MGLL (0.37) | MGLL | |
| SCHEMBL15371562 | 0.86 | KMT2A (0.32) | MGLL | |
| SCHEMBL14615810 | 0.83 | PARL (0.32) | MGLL | |
| SCHEMBL19704968 | 0.82 | PSMB8 (0.32) | MGLL | |
| SCHEMBL14769177 | 0.82 | MGLL (0.30) | MGLL | |
| SCHEMBL11993176 | 0.82 | KDM4E (0.31) | MGLL | |
| SCHEMBL22549169 | 0.82 | MGLL (0.30) | MGLL | |
| SCHEMBL12482068 | 0.82 | GLA (0.36) | — | |
| SCHEMBL13286374 | 0.81 | MGLL (0.32) | MGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110257111-A1 | Hydroxyethlamino Sulfonamide Derivatives | CONCERT PHARMACEUTICALS, INC. | 2011-10-20 | — | — | US | disclosed |
| US-20110166167-A1 | BICYCLIC HETEROCYCLE DERIVATIVES AND METHODS OF USE THEREOF | SCHERING CORPORATION (US) | 2011-07-07 | — | — | US | disclosed |
| US-20110159305-A1 | Intermediates And Methods For Forming Passivated Surfaces On Oxide Layers And Articles Produced Thereby | APPLIED BIOSYSTEMS, LLC (US) | 2011-06-30 | — | — | US | disclosed |
| US-20100311184-A1 | AZO HETEROCYCLIC DYES AND THEIR BIOLOGICAL CONJUGATES | AAT BIOQUEST, INC. (US) | 2010-12-09 | — | — | US | disclosed |
| US-20100305173-A1 | HYDROXYETHYLAMINO SULFONAMIDE DERIVATIVES | CONCERT PHARMACEUTICALS, INC. (US) | 2010-12-02 | — | — | US | disclosed |
| US-20100113589-A1 | Deuterated darunavir | CONCERT PHARMACCUTICALS, INC. (US) | 2010-05-06 | — | — | US | disclosed |
| US-20100016547-A1 | Glycosilated Peptide and Medicine Comprising It as an Effective Ingredient | NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (JP) | 2010-01-21 | — | — | US | disclosed |
| US-20070293530-A1 | SULFAMIDE AND SULFAMATE DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS | METHYLGENE INC. (CA) | 2007-12-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016547-A1 | Glycosilated Peptide and Medicine Comprising It as an Effective Ingredient | GLP1R, VIP, IAPP | MGLL 173/4885 |
| US-20100305173-A1 | HYDROXYETHYLAMINO SULFONAMIDE DERIVATIVES | STS, PRSS1, PRSS3 | MGLL 2540/4885 |
| US-20110166167-A1 | BICYCLIC HETEROCYCLE DERIVATIVES AND METHODS OF USE THEREOF | GPR119, GCGR, GLP1R | MGLL 651/4885 |
| US-20070293530-A1 | SULFAMIDE AND SULFAMATE DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS | HDAC1, HDAC11, HAT1 | MGLL 2841/4885 |
| US-20100311184-A1 | AZO HETEROCYCLIC DYES AND THEIR BIOLOGICAL CONJUGATES | PAICS, DNTT, TK1 | MGLL 4854/4885 |
| US-20110257111-A1 | Hydroxyethlamino Sulfonamide Derivatives | HTRA1, PRSS8, PRSS1 | MGLL 1754/4885 |
| US-20100113589-A1 | Deuterated darunavir | SAMHD1, DUT, DNPEP | MGLL 3872/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.